GENEVA, July 9 -- MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. filed a patent application (CN2025/147916) for “USE OF ANTI-NECTIN-4 ANTIBODY-DRUG CONJUGATE IN TREATING CANCER AND METHOD THEREFOR”. With publication no. WO/2026/145668, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 47/68
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....